Luye Pharma Group (HKG:2186) said five new products were added to China's latest list of drugs eligible for reimbursement, according to a Hong Kong bourse filing Sunday.
Shares of the company gained over 1% in morning trade Monday.
Of the five products, opioid painkiller Mimeixin and schizophrenia treatment Ruibailai were added to China's National Reimbursement Drug List for the first time, while lung cancer treatment Zepzelca was included in the Commercial Insurance Innovative Drug List.
Meanwhile, cancer drug Baituowei and chronic schizophrenia treatment Rykindo's inclusion was renewed, the firm said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments